These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36432640)

  • 1. Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study.
    Tallarico M; Palleria C; Ruffolo L; Spagnuolo R; Naturale MD; De Francesco AE; De Sarro C; Romeo R; Citraro R; Doldo P; Abenavoli L; Gallelli L; Luzza F; Leo A; De Sarro G
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy.
    Roberti R; Iannone LF; Palleria C; De Sarro C; Spagnuolo R; Barbieri MA; Vero A; Manti A; Pisana V; Fries W; Trifirò G; Naturale MD; Larussa T; De Francesco AE; Bosco V; Donato di Paola E; Citraro R; Luzza F; Bennardo L; Rodinò S; Doldo P; Spina E; Russo E; De Sarro G
    Curr Med Res Opin; 2020 Sep; 36(9):1457-1463. PubMed ID: 32573307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project.
    Barbieri MA; Viola A; Cicala G; Spina E; Fries W
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
    Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases.
    Sah J; Teeple A; Muser E; Gutierrez C; Dassopoulos T
    Curr Med Res Opin; 2022 Jul; 38(7):1093-1101. PubMed ID: 35475385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.
    Hahn GD; LeBlanc JF; Golovics PA; Wetwittayakhlang P; Qatomah A; Wang A; Boodaghians L; Liu Chen Kiow J; Al Ali M; Wild G; Afif W; Bitton A; Lakatos PL; Bessissow T
    World J Gastroenterol; 2022 Sep; 28(33):4823-4833. PubMed ID: 36156919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.
    Iannone LF; Bennardo L; Palleria C; Roberti R; De Sarro C; Naturale MD; Dastoli S; Donato L; Manti A; Valenti G; D'Amico D; D'Attola S; De Francesco AE; Bosco V; Donato Di Paola E; Nisticò SP; Citraro R; Russo E; De Sarro G
    PLoS One; 2020; 15(11):e0241575. PubMed ID: 33141869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network.
    Romeo AC; Ventimiglia M; Dipasquale V; Orlando A; Citrano M; Pellegrino S; Accomando S; Cottone M; Romano C
    Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):223-229. PubMed ID: 31204314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence, Dosing, and Other Treatment Patterns Among Crohn's Disease Patients Initiating Biologics in United States.
    Teeple A; Sah J; Mallampati R; Adams C; Waters D; Muser E
    Crohns Colitis 360; 2021 Oct; 3(4):otab076. PubMed ID: 36777272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region.
    Gagliardi A; Iaquinta FS; Grembiale RD; De Sarro C; Fabiano A; Fraija D; Palleria C; Romeo R; De Francesco AE; Naturale MD; Citraro R; Gallelli L; Leo A; De Sarro G
    Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365146
    [No Abstract]   [Full Text] [Related]  

  • 11. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
    Macaluso FS; Ventimiglia M; Fries W; Viola A; Cappello M; Scrivo B; Magnano A; Pluchino D; Camilleri S; Garufi S; Mitri RD; Mocciaro F; Magrì G; Ferracane C; Citrano M; Graziano F; Bertolami C; Renna S; Orlando R; Rizzuto G; Cottone M; Orlando A;
    Dig Liver Dis; 2020 Dec; 52(12):1461-1466. PubMed ID: 32601033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation.
    Barberio B; Savarino EV; Card T; Canova C; Baldisser F; Gubbiotti A; Massimi D; Ghisa M; Zingone F
    Intest Res; 2022 Jan; 20(1):114-123. PubMed ID: 34333908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series.
    Larussa T; Basile A; Palleria C; Iannelli C; Vero A; Giubilei L; De Sarro C; Suraci E; Marasco R; Imeneo M; Russo E; Abenavoli L; De Sarro G; Luzza F
    Med Pharm Rep; 2021 Jul; 94(3):289-297. PubMed ID: 34430850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.
    Barbieri MA; Cicala G; Cutroneo PM; Gerratana E; Palleria C; De Sarro C; Vero A; Iannone L; Manti A; Russo E; De Sarro G; Atzeni F; Spina E
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32344563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases.
    Shi Y; He W; Zhong M; Yu M
    Genomics; 2021 Jul; 113(4):1988-1998. PubMed ID: 33872704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).
    Palleria C; Iannone L; Leporini C; Citraro R; Manti A; Caminiti M; Gigliotti P; Grembiale RD; L'Andolina M; Muccari G; Naturale MD; Olivo D; Pagano Mariano G; Pellegrini R; Varcasia G; Abdalla K; Russo E; Ursini F; De Sarro G
    PLoS One; 2018; 13(10):e0205134. PubMed ID: 30356301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
    Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Welty M; Mesana L; Padhiar A; Naessens D; Diels J; van Sanden S; Pacou M
    Curr Med Res Opin; 2020 Apr; 36(4):595-606. PubMed ID: 31960724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.